XML 92 R83.htm IDEA: XBRL DOCUMENT v3.19.2
Liquidity (Details) - USD ($)
 3 Months Ended 7 Months Ended 10 Months Ended 12 Months Ended
Apr. 25, 2019
Apr. 24, 2019
Sep. 21, 2018
Aug. 28, 2018
Jul. 25, 2018
Jun. 01, 2018
Nov. 28, 2017
Sep. 05, 2017
Mar. 31, 2019
Dec. 31, 2018
Mar. 31, 2018
Dec. 31, 2018
Mar. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
May 24, 2018
May 23, 2018
Dec. 31, 2016
Liquidity [Line Items]                                    
Net loss                 $ 3,150,000   $ 4,409,000     $ 12,634,000 $ 22,686,000      
Accumulated deficit                 (417,533,000) $ (414,383,000)   $ (414,383,000) $ (417,533,000) (414,383,000) (401,749,000)      
Net cash used in operating activities                 $ (3,270,000)   (4,119,000)     $ (11,975,000) (18,128,000)      
Substantial doubt about going concern, description                 These factors raise substantial doubt about the Company’s ability to continue as a going concern.         These factors raise substantial doubt about the Company’s ability to continue as a going concern        
Cash and cash equivalents                 $ 3,872,000 5,261,000   5,261,000 3,872,000 $ 5,261,000 9,550,000     $ 12,600,000
Minimum cash/cash equivalents covenant                 2,000,000 2,000,000   2,000,000 2,000,000 2,000,000        
Proceeds from sale of common stock, net                 1,919,000   (150,000)     0 0      
Common stock issued (in shares)         6,723   10,000                      
Number of shares callable by warrants (in shares)                               2,300,000 23,400,000  
Proceeds from issuance warrants         $ 5,700,000   $ 8,800,000                      
Common stock issued, value                 $ 1,873,000   $ 27,000     $ 1,624,000 $ 12,716,000      
Subsequent Event [Member] | Cytori Ltd. and Cell Therapy Assets [Member]                                    
Liquidity [Line Items]                                    
Cash proceeds from sale of subsidiary   $ 3,400,000                                
Subsequent Event [Member] | Cytori Ltd. and Cell Therapy Assets [Member] | Amendment to Loan and Security Agreement [Member]                                    
Liquidity [Line Items]                                    
Payments for principal, interest and fees   $ 1,700,000                                
Subsequent Event [Member] | Cytori Therapeutics, K.K. and Cell Therapy Assets used in Japan [Member]                                    
Liquidity [Line Items]                                    
Cash proceeds from sale of subsidiary $ 2,500,000                                  
Subsequent Event [Member] | Cytori Therapeutics, K.K. and Cell Therapy Assets used in Japan [Member] | Amendment to Loan and Security Agreement [Member]                                    
Liquidity [Line Items]                                    
Payments for principal, interest and fees $ 1,400,000                                  
Nasdaq Stock Market LLC [Member]                                    
Liquidity [Line Items]                                    
Number of consecutive business days no longer able to meet the required closing bid price of common stock       30 days       30 days                    
Minimum bid price of common stock required for Nasdaq listing rule       $ 1.00       $ 1.00                    
Grace period provided with minimum bid price for Nasdaq listing rule       180 days       180 days                    
Grace date for minimum bid price requirement for Nasdaq listing       Feb. 25, 2019       Mar. 05, 2018                    
Common stock minimum bid price required to regain compliance       $ 1.00       $ 1.00                    
Number of consecutive business days required to regain compliance       10 days       10 days                    
Date to regain compliance after meeting continued listing requirement       Aug. 26, 2019       Sep. 04, 2018                    
Additional grace period provided with minimum bid price to regain compliance       180 days       180 days                    
Description of compliance with minimum bid price requirement       We were granted an additional compliance period of 180 calendar days, or until August 26, 2019, in which to regain compliance after meeting the continued listing requirement for market value of publicly held shares and all other initial listing standards for the Nasdaq Capital Market, with the exception of the bid price requirement, and providing notice to Nasdaq staff of our intent to cure the deficiency during this second compliance period, by effecting a reverse stock split, if necessary.                   We were granted an additional compliance period of 180 calendar days, or until August 26, 2019, in which to regain compliance after meeting the continued listing requirement for market value of publicly held shares and all other initial listing standards for the Nasdaq Capital Market, with the exception of the bid price requirement, and providing notice to Nasdaq staff of our intent to cure the deficiency during this second compliance period, by effecting a reverse stock split, if necessary.        
Series C Convertible Preferred Stock [Member]                                    
Liquidity [Line Items]                                    
Number of convertible shares converted into common stock (in shares)         168,478                          
Number of shares callable by warrants (in shares)         7,059,150                          
Common stock issued, value                           $ 3,041,000        
Common Stock [Member]                                    
Liquidity [Line Items]                                    
Common stock issued (in shares)         6,723   10,000   139,855   201     92,169 24,474      
Number of shares callable by warrants (in shares)         50   36,000                      
Warrant exercise price (in dollars per share)         $ 39.93   $ 166.65                      
Common Stock [Member] | Series C Convertible Preferred Stock [Member]                                    
Liquidity [Line Items]                                    
Number of convertible shares converted into common stock (in shares)                 1,652         80,868        
Common Stock [Member] | B. Riley FBR [Member] | Sales Agreement [Member]                                    
Liquidity [Line Items]                                    
Proceeds from sale of common stock, net                       $ 1,700,000 $ 3,800,000          
Common stock issued (in shares)                       1,584 200,000          
Common Stock [Member] | Lincoln Park [Member]                                    
Liquidity [Line Items]                                    
Proceeds from sale of common stock, net                   $ 300,000                
Common stock issued (in shares)                 0 12,802                
Common stock issued, value     $ 5,000,000                              
Period exercisable from the date of issuance     24 months                              
Minimum [Member]                                    
Liquidity [Line Items]                                    
Unrestricted cash and cash equivalents                 $ 2,000,000 $ 2,000,000   $ 2,000,000 $ 2,000,000 $ 2,000,000        
Maximum [Member] | Common Stock [Member] | B. Riley FBR [Member] | Sales Agreement [Member]                                    
Liquidity [Line Items]                                    
Proceeds from sale of common stock, net           $ 6,500,000